IMMUNOHISTOCHEMISTRY CD99 MIC-2 Test
Test Name: IMMUNOHISTOCHEMISTRY CD99 MIC-2 Test
Components: CD99 protein detection
Price: 410.0 AED
Sample Condition: Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Report Delivery: Sample Daily by 6 pm; Report Block: 5 days, Tissue Biopsy: 5 days, Tissue large complex: 7 days
Method: Immunohistochemistry
Test Type: Cancer
Doctor: Oncologist, Pathologist
Test Department: DNA Labs UAE
Pre Test Information
Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Test Details
The immunohistochemistry CD99 (MIC-2) test is a diagnostic tool used in pathology to detect the presence of CD99 protein in tissue samples. CD99 is a glycoprotein that is normally found on the cell surface of various tissues, including lymphocytes, endothelial cells, and fibroblasts.
The CD99 (MIC-2) test is commonly used in the diagnosis of certain types of tumors, such as Ewing sarcoma, primitive neuroectodermal tumors (PNET), and synovial sarcoma. These tumors often express the CD99 protein at high levels, making it a useful marker for their identification.
The test involves staining tissue sections with specific antibodies that recognize the CD99 protein. The antibodies are usually conjugated with a fluorescent or enzymatic label, which allows for visualization of the protein under a microscope. If the tissue sample shows positive staining for CD99, it suggests the presence of CD99-expressing tumor cells.
The immunohistochemistry CD99 (MIC-2) test is often performed alongside other diagnostic tests, such as histopathology and molecular genetic analysis, to confirm the diagnosis of certain tumors. It can also be used to monitor the response to treatment and detect any recurrence of the tumor.
Overall, the immunohistochemistry CD99 (MIC-2) test is a valuable tool in the diagnosis and management of certain tumors, providing important information for treatment planning and prognosis.
Test Name | IMMUNOHISTOCHEMISTRY CD99 MIC-2 Test |
---|---|
Components | |
Price | 410.0 AED |
Sample Condition | Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
Report Delivery | Sample Daily by 6 pm; Report Block: 5 days Tissue Biopsy: 5 days Tissue large complex : 7 days |
Method | Immunohistochemistry |
Test type | Cancer |
Doctor | Oncologist, Pathologist |
Test Department: | |
Pre Test Information | Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
Test Details |
The immunohistochemistry CD99 (MIC-2) test is a diagnostic tool used in pathology to detect the presence of CD99 protein in tissue samples. CD99 is a glycoprotein that is normally found on the cell surface of various tissues, including lymphocytes, endothelial cells, and fibroblasts. The CD99 (MIC-2) test is commonly used in the diagnosis of certain types of tumors, such as Ewing sarcoma, primitive neuroectodermal tumors (PNET), and synovial sarcoma. These tumors often express the CD99 protein at high levels, making it a useful marker for their identification. The test involves staining tissue sections with specific antibodies that recognize the CD99 protein. The antibodies are usually conjugated with a fluorescent or enzymatic label, which allows for visualization of the protein under a microscope. If the tissue sample shows positive staining for CD99, it suggests the presence of CD99-expressing tumor cells. The immunohistochemistry CD99 (MIC-2) test is often performed alongside other diagnostic tests, such as histopathology and molecular genetic analysis, to confirm the diagnosis of certain tumors. It can also be used to monitor the response to treatment and detect any recurrence of the tumor. Overall, the immunohistochemistry CD99 (MIC-2) test is a valuable tool in the diagnosis and management of certain tumors, providing important information for treatment planning and prognosis. |